Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases
Usefulness of a novel and rapid assay system for fecal calprotectin in pediatric patients with inflammatory bowel diseases
复制标题
DOI：
10.1111/jgh.12578
复制
发表时间：
2014-07-01
影响因子：
4.1
通讯作者：
Tamai, Hiroshi
中科院分区：
文献类型：
--
作者：
Inoue, Keisuke;Aomatsu, Tomoki;Tamai, Hiroshi
背景和目的：粪便钙卫蛋白（FC）已成为炎症性肠病（IBD）肠道炎症的可靠生物标志物。然而，一个简单，快速的检测，以取代传统的ELISA是必要的，在临床实践中更广泛的使用。在这项研究中，我们研究了一种新的方法来测量FC使用胶体金聚集（CGA）测定评估粘膜炎症在儿科IBDs.Methods的有用性：FC水平测定ELISA和CGA测定309粪便样本（溃疡性结肠炎[UC]：131;克罗恩病[CD]：121;健康对照：57）。结果：两种方法测定的FC值之间有较强的相关性（r = 0.98，P < 0.01），且两种方法测定的FC值之间无显著性差异（r = 0.98，P> 0.05）。CGA测定的FC水平与UC和CD的内镜评分（r = 0.70，P < 0.01）和（r = 0.58，P < 0.01）密切相关。在内镜下缓解的UC患者中，CGA测定的FC水平（中位数：31.5 μ g/g，n = 14）与健康对照组一样低。对于患者在临床缓解，但表现出积极的状态，内镜下，FC是更有可能是异常的比常用的实验室markets.Conclusions：我们简单，快速的检测系统具有良好的性能，用于评估炎症性肠病的粘膜炎症，可以取代ELISA。该检测系统的实际应用使我们能够在临床实践中更广泛地使用FC测量。
Background and Aim: Fecal calprotectin (FC) has become a reliable biomarker for intestinal inflammation in inflammatory bowel diseases (IBDs). However, a simple and rapid assay to replace conventional ELISA is necessary for wider use in clinical practice. In this study, we investigated the usefulness of a novel method for measuring FC using a colloidal gold aggregation (CGA) assay for assessing mucosal inflammation in pediatric IBDs.Methods: FC levels were determined by ELISA and CGA assay in 309 fecal samples (ulcerative colitis [UC]: 131; Crohn's disease [CD]: 121; healthy controls: 57). For endoscopic evaluation, the modified Matts' grading system for UC and the simple endoscopic score for CD were used.Results: A strong correlation was found between the FC values determined by the two methods (r = 0.98, P < 0.01). FC levels, determined by CGA assay, strongly correlated with the endoscopic score for UC (r = 0.70, P < 0.01) and CD (r = 0.58, P < 0.01). In the UC patients with endoscopic remission, the FC levels determined by CGA assay (median: 31.5 mu g/g, n = 14) were as low as in healthy controls. For patients in clinical remission but showing an active status endoscopically, FC was more likely to be abnormal than commonly used laboratory markers.Conclusions: Our simple and rapid assay system has excellent performance for assessing mucosal inflammation of IBDs and can be replaced for ELISA. Practical application of this assay system enables us to use FC measurement more widely in clinical practice.